Cara’s Korsuva Impresses Against Pruritus In Hemodialysis Patients

Pivotal KALM-2 Study Meets Primary Endpoint

Cara Therapeutics and licensee Vifor Pharma have released positive topline data from the KALM-2 study in chronic kidney disease patients with moderate-to-severe pruritus undergoing hemodialysis, using a first-in-class selective kappa opioid receptor agonist which does not enter the CNS.  

Arm_Scratching
• Source: Shutterstock

Top-line results from KALM-2, the second of two Phase III studies of Cara Therapeutics Inc.'s pruritus therapy, Korsuva (CR845/difelikefalin), have confirmed the efficacy of the intravenous therapy to treat the condition in patients with chronic kidney disease on dialysis.

Results from the first Phase III trial, KALM-1, outlined in May 2019, were favorably received by analysts, who said they...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category